FTC closes probe of Resonetics’ $900M medical nitinol purchase

The Federal Trade Commission concluded its investigation of Resonetics’ planned $900 million acquisition of SAES Getters’ medical nitinol business, the companies announced Wednesday.

Menlo Park, California-based Resonetics, which specializes in engineering and manufacturing for medical device products, set out plans in January to buy Memry Corp. and SAES Smart Materials from Italy-based parent company SAES Getters. SAES did not specify whether the FTC will require additional terms for the acquisition to go through. 

The purchase would give Resonetics a leading supplier of nitinol for the medical device industry, Resonetics CEO Tom Burns said in a January statement. Nitinol is a metal alloy with unique shape memory and elastic properties. It’s used in structural heart, peripheral vascular, electrophysiology, neurovascular and orthopedics procedures, Burns said. 

The companies received a second request for information from the FTC in March, under the Hart-Scott-Rodino Antitrust Improvements Act. In 2022, SAES Getters’ medical nitinol business reported revenues of 121.97 million euros, a 26% year-over-year increase excluding the effect of foreign exchange rates. 

SAES said the companies will clarify in the next few days when they expect the transaction to close.

Long Q4 Lifts Organigram Revenue

Organigram Reports Fiscal 2023 Results¹ Domestic share growth in several key categories continues to be driven by innovation excellence and industry-leading R&D. Organigram continues to

Read More »